Kalderos

We've made some BIG announcements in the past week, and we are so excited to continue with the introduction of our newest team members! 👋 Please give a warm welcome to Mary Braddock, Kristi Corriston, Sam J., Osman Meer, Courtney Quirk, Tiffany Singer, and Annie Stehly. We are thrilled to have each of these talented individuals on our team!

🎉We're coming off an incredible 3 days at #MDRP Conference! It was a whirlwind of excitement as we discussed today's landscape of drug discount management with you all, and launched our new end-to-end drug discount management platform, Truzo. Here are some highlights: 🌟Our CEO, Angie Franks, took the main stage to discuss how we can bring some clarity to 340B. 💪🏽 Gavin Magaha, Kate Flathers, and Ariel Pekelis showcased the power of Truzo and how to manage all your drug discount programs with confidence 🔥We heard from the legend himself, Adam Fein, at our fireside chat 🍾We shined Truzo-blue on the Chicago Architecture Center while customers, industry changemakers, and our team mixed and mingled for dinner and drinks. 🙏🏼A huge thanks to all of our customers, #TeamK, Informa Connect, Chicago Architecture Center, Adam Fein, and industry friends and acquaintances for coming together to build something special! We will post more pictures and Truzo fun in the coming weeks!

🎉 🎉 Not only are we recognizing Marlene Barajas in September's Employee Spotlight, we're also celebrating her recent promotion to Data Engineer II! Congratulations Marlene! We are lucky to work with you!

Nationally recognized healthcare and life sciences legal expert William Sarraille, who is also one of our board members, recently wrote an enlightening, concise and easy-to-understand explanation on his very active LinkedIn page of one of the several dysfunctional aspects of the 340B Drug Pricing Program. Bill explains how the Medicare Transaction Facilitator (MTF), designed to help covered entities and drug manufacturers coordinate 340B drug discounts, is in reality, a “toothless monstrosity.” The MTF offers neither stakeholder in the transaction data transparency or confirmation that appropriate discounts have been granted, creating confusion and mistrust down the road, and worse yet, care delays for patients. “It’s a train wreck,” Bill writes. “The only way thru this impasse is to cooperate.” Read Bill’s full post and follow his page here: https://lnkd.in/gsdzfYQq | #340B #340BReform #MTF #DrugManufacturers #CoveredEntities

Built In Boston, a career and news site for tech professionals, recently explored how our company empowers team members to be “innovative, creative, scrappy and bold” in an article posted earlier this month. The article features insights from our Senior Director of Engineering Anjan Samanta, Project Manager Sylvia Ho, PharmD, and Vice President of Finance Kelsey Andriatch, CPA, about what drew them to Kalderos and what they love about being part of our team. Kelsey perfectly sums up her experience this way: “I’ve felt challenged and pushed to be my best every day, and I’ve felt support from every level on the totem pole.” Learn more about our exceptional company and culture here: https://lnkd.in/gN_4b6WP #CompanyNews #HR #HealthTech #CompanyCulture #EmployeeEngagement

The state of Pennsylvania paid an excess of $7 million in Medicaid prescription drug benefits in 2022 due to a lack of oversight by its Department of Human Services and “spread pricing” by its pharmacy benefit manager (PBM), according to a report released in August from the state’s Auditor General Timothy L. DeFoor, M.S. The state’s managed care organization administrating its Medicaid program also partnered with a PBM to manage the prescription drug benefits. Auditors found undisclosed spread pricing where the PBM was not reporting transmission fees charged to pharmacies. “This lack of transparency resulted in overstated pharmacy data,” according to a statement from DeFoor, who was quoted: “PBMs are counting on the fact that no one is checking their reporting so they can get paid a higher rate and still collect a fee from the pharmacy…[W]hat really needs to happen here are changes in the law.” This report echoes news about a similar Medicaid Drug Rebate Program audit we posted about last week from Maryland that found $12.4 million in uncollected rebates. The full statement from DeFoor and report findings are here: https://lnkd.in/gEZFCbzj #MedicaidDrugRebateProgram #MDRP #MedicaidMCO #PBM #DataTransparency

🎉 Please join us in welcoming Hawo Ibrahim and Heidi Haring as the newest members of the Kalderos team! Our customers are in great hands with Hawo and Heidi's experience and care, and we are so excited to work with and learn from them. Welcome to team K! #biastoaction #oneteam #leadbyexample #dumpsterdivingdatamaven

As Kalderos grows, we are embedding career growth in our culture. Our team members are thriving in an environment that values innovation, mentorship and personal development. Visit Built In to hear firsthand from Kelsey Andriatch, CPA, Sylvia Ho, PharmD, and Anjan Samanta how Kalderos is shaping the future of health tech by empowering employees to reach new heights: https://lnkd.in/g36cke6Z

Our CFO Jim Sparks was quoted in a new article on the popular financial news website PYMNTS concerning the potential impact of AI on senior executives in his role. Jim points out in the article, however, that while adoption of Generative AI technology, such as ChatGPT, among CFOs may be new, other types of AI have been used in financial senior management for years with success. “In a perfect world, I think artificial intelligence won’t replace humans,” Jim told the publication. “But it will make humans more effective by unlocking insights and making projections more accurate.” The full article is available here: https://lnkd.in/gBdCWfSQ | #AI #GenerativeAI #AIinHealthcare #AIinFinance #CompanyNews

Dual-eligible beneficiaries – older adults receiving both Medicare and Medicaid – tend to pay less out-of-pocket for their prescription drugs when they enroll in Dual-Eligible Special Needs Plans (D-SNPs) versus only receiving traditional Medicare benefits, according to study results released this summer in JAMA Health Forum. Researchers note that D-SNP enrollees who received a higher level of care coordination and benefits integration for the two government-funded programs also tended to have a better experience of care than beneficiaries in less-integrated D-SNPs or who received Medicare alone. Enrollees in more integrated D-SNPs also report less overall financial burden, although out-of-pocket spending between the two types of dual-eligible managed care programs was largely identical. The full study is available here: https://lnkd.in/gJAG_k34 | #Medicaid #DualEligible #DSNP #PrescriptionDrugCosts #MCO